Logo Image
|Articles|September 16, 1998

MBI’s Widder leaves company

Contrast agent developer Molecular Biosystems of San Diego announced this month the resignation of Dr. Kenneth Widder as chairman of the board, effective immediately. The company said that Widder’s departure was part of an executive succession plan

Contrast agent developer Molecular Biosystems of San Diego announced this month the resignation of Dr. Kenneth Widder as chairman of the board, effective immediately. The company said that Widder’s departure was part of an executive succession plan that the company has been considering for some time. MBI has not named Widder’s replacement.

Latest CME

25th Annual International Congress on the Future of Breast Cancer® East
Video

25th Annual International Congress on the Future of Breast Cancer® East

Joyce O’Shaughnessy, MD

View more
25th Annual International Congress on the Future of Breast Cancer® West
Video

25th Annual International Congress on the Future of Breast Cancer® West

Sara A. Hurvitz, MD, FACP; Joyce O’Shaughnessy, MD

View more
Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified
Multimedia

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

View more
Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care
Multimedia

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

View more
Tennessee Oncology Practice Society
Virtual Event

Tennessee Oncology Practice Society

2 Sessions are Available!

View more